Recombinant activated factor VIIa treatment for refractory hemorrhage in infants. - Wikidata - awgldk - TriplyDB

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

http://www.wikidata.org/entity/Q34274196

about

Recombinant Activated Factor VIIa (rFVIIa) Treatment in Very-Low-Birth-Weight (VLBW) Premature Infants with Acute Pulmonary Hemorrhage: A Single-Center, Retrospective Study.

P2860

Q39202769-90EF8200-23D8-43D8-B1DC-F7EDECCB90DB

P2860

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

http://www.wikidata.org/entity/Q34274196

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@ast

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@en

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@nl

type

label

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@ast

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@en

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@nl

prefLabel

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@ast

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@en

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@nl

P1433

Q34274196-B0FA6A71-A11A-428E-A877-C0740EBA1644

P1476

Q34274196-E235D57E-144D-489D-8277-54EA536BDD57

P2093

Q34274196-09AA49F2-50F1-4FEC-910E-1D453C1F23A9

Q34274196-15F08C16-8A72-4EC0-AC3E-033E3CB2680E

Q34274196-4BE18C7B-D8BA-4668-AA87-44328DF07970

Q34274196-69F08652-1510-4633-8BB0-38AA102A8755

Q34274196-B02B9A97-34D2-418C-87DF-D92F9FDA63A3

Q34274196-C1851FAD-30B5-4705-B085-FF0A39EF3FDD

Q34274196-C3A174B1-944E-4DFE-B0EB-6474AE828B87

Q34274196-CAD04EBF-719F-42E2-B5A0-01E58E0C7A0A

P2860

Q34274196-00BF85BF-A305-4277-BA9A-65927D3FBAF7

Q34274196-2B65693D-4B2C-4BBD-ADDA-75BEA1BB5A02

Q34274196-2D2E2BF8-B2C6-4E94-855E-318011AC9184

Q34274196-3097F8DD-F0FC-4A26-BF36-F0B5CE9B382C

Q34274196-3D5239CC-BF63-41C7-98C5-1D282E6B88EB

Q34274196-5D3CA9AA-EC26-4654-BE3E-1F445F22D138

Q34274196-5DA526AC-113A-4FB1-8D82-C3A1666B88F6

Q34274196-6CF814D8-6426-45A3-86BF-65174F1AF576

Q34274196-719AB544-4D9D-41F9-8D58-7DE6B03FB5DF

Q34274196-88E44ADB-7BD2-4367-9A2C-F7E0040E0460

P2888

Q34274196-D99495FD-9AE9-4352-873D-0B36ECF28924

P304

Q34274196-B678110C-02BB-4C21-B918-B6DFEFD71D8F

P31

Q34274196-4B3A679D-063A-42B0-BFB3-46FB89BD810C

P356

Q34274196-7FB13976-CE3E-4915-8FFF-73E6AECEADE4

P433

Q34274196-283E3D26-62A1-4736-9FCB-64600737E19B

P478

Q34274196-0E135D54-9BCB-496F-B253-2767783B3EF9

P577

Q34274196-D420F19C-5D30-4EC7-A4EA-0D9929BF131F

P5875

Q34274196-691C6B1B-A2C7-4DDA-9C72-02945436BFD3

P6179

Q34274196-1D4B558D-D036-41C3-B505-1E92D0A6409D

P698

Q34274196-AA242544-9C06-40DE-B26C-8839CBF0BAD7

P932

Q34274196-2F8AC076-7D1E-42A0-8DCE-045826EE8771

P356

P1433

Journal of Perinatology

P1476

Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

@en

P2093

C D Thornburg

http://www.w3.org/2001/XMLSchema#string

C M Cotten

http://www.w3.org/2001/XMLSchema#string

C N Dang

http://www.w3.org/2001/XMLSchema#string

L I Katakam

http://www.w3.org/2001/XMLSchema#string

M Bidegain

http://www.w3.org/2001/XMLSchema#string

N Chandler

http://www.w3.org/2001/XMLSchema#string

P B Smith

http://www.w3.org/2001/XMLSchema#string

R N Goldberg

http://www.w3.org/2001/XMLSchema#string

P2860

Recombinant factor VIIa for treatment of massive liver fracture in a premature infant.

Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery.

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature.

A comprehensive review of rFVIIa use in a tertiary care pediatric center.

Recombinant activated factor VII use in critically ill infants with active hemorrhage.

Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma.

Necrotizing enterocolitis: treatment based on staging criteria.

Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass.

Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.

P2888

P304

188-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JP.2010.85

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45424442

http://www.w3.org/2001/XMLSchema#string

P6179

1032736104

http://www.w3.org/2001/XMLSchema#string

P698

20671714

http://www.w3.org/2001/XMLSchema#string

P932

2972386

http://www.w3.org/2001/XMLSchema#string